← SVN001
What podcasts say about SVN001
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about SVN001
3 statements · 3 positive
SVN-001’s active arm was 50% better than placebo on the trial outcome.
“the active arm, the 001 arm, was 50% better than the placebo.”
Open the episode · S12 Ep6: Sunday Roast - Mantle Resilience Plc,Xtract Resources,Bezant Resources,Solvonis Therapeutics plc, African Pioneer, Kendrick Resources, Active Energy Group PLC, Critical Mineral Resources & Galileo Resources #MNTL #XTR #BZT #SVNS #AFP #KEN #AEG #CMRS #GLRListen at 53:06
EU trial data could improve SVN001’s probability of EU marketing approval.
“what our hope would be that if we have EU data in the trial, it would increase the probability of an accepted marketing authorization or marketing approval in certain EU countries in due course.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 3:59
Adding EU data would significantly increase SVN001’s strategic optionality.
“by potentially adding in EU data, we increase the, let's just call it optionality for that program, I believe, significantly.”
Open the episode · S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 6:38
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.